Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients...

Area of Science:

• Gastroenterology and Rheumatology
• Clinical Pharmacology
• Patient Safety

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently associated with gastrointestinal (GI) damage.
• The CONDOR trial identified a hemoglobin drop (≥2 g/dL) of GI origin as a primary endpoint event.
• This adverse event poses a significant clinical risk during long-term NSAID therapy.

Purpose of the Study:

• To identify risk factors for decreased hemoglobin or hematocrit in patients undergoing NSAID treatment.
• To analyze predictors of clinically significant blood loss in osteoarthritis patients.

Main Methods:

• A post hoc analysis of the CONDOR trial was performed on the intention-to-treat population.
• Clinically significant blood loss was defined as a hemoglobin drop ≥2 g/dL and/or hematocrit drop ≥10%, with GI origin.
• Stepwise logistic regression evaluated fifteen potential risk factors, with a significance level of <0.20 α.

Main Results:

• 1.7% of osteoarthritis patients (64/3774) experienced decreased hemoglobin/hematocrit attributed to GI causes.
• Significant risk factors identified included elevated baseline C-reactive protein (CRP) levels, history of gastritis/GI intolerance, and positive Helicobacter pylori status.
• Increasing age and body mass index (BMI) were also associated with a higher risk of significant blood loss.

Conclusions:

• Monitoring hemoglobin levels is crucial for all osteoarthritis patients, particularly those with identified risk factors.
• Risk factors include advanced age, higher BMI, prior gastritis or GI intolerance, elevated CRP (>1 mg/dL), and H. pylori positivity.
• Early identification and monitoring can inform clinical management and mitigate risks associated with NSAID use.